Table 1 Baseline Clinical and Laboratory characteristics of patients with baseline TG ≥200 mg/dl by original study allocation
|  | Bezafibrate group (n = 234) | Placebo group (n = 224) | P value |
|---|---|---|---|
Clinical characteristics | |||
 Age, years | 58 ± 7 | 58 ± 7 | 0.62 |
 Male | 210 (90) | 199 (89) | 0.75 |
 Hypertension | 78 (33) | 80 (36) | 0.61 |
 DM | 28 (12) | 21 (9) | 0.37 |
 BMI, kg/m2 | 28 ± 4 | 28 ± 3 | 0.81 |
 NYHA functional class ≥2 | 71 (30) | 53 (25) | 0.41 |
 AP class ≥2 | 72 (30) | 53 (23) | 0.40 |
 Prior MI | 173 (74) | 171 (76) | 0.60 |
 COPD | 4 (2) | 8 (4) | 0.22 |
Medical therapy | |||
 Anti-platelets | 157 (67) | 155 (69) | 0.63 |
 Beta-blockers | 116 (49) | 94 (42) | 0.10 |
 Nitrates | 114 (51) | 127 (54) | 0.47 |
 Ca2+-blockers | 107 (46) | 116 (52) | 0.11 |
 ACE inhibitors | 30 (13) | 27 (12) | 0.80 |
 Diuretics | 27 (11) | 36 (16) | 0.16 |
 Non-study LLD | 136 (58) | 122 (54) | 0.40 |
Laboratory values | |||
 Glucose | 104 ± 18 | 103 ± 19 | 0.76 |
 Total cholesterol | 215 ± 18 | 216 ± 18 | 0.46 |
 HDL-C | 31 ± 5 | 32 ± 5 | 0.14 |
 LDL-C | 138 ± 17 | 140 ± 17 | 0.74 |
 Triglycerides | 235 ± 25 | 235 ± 29 | 0.94 |
 Fibrinogen | 361 ± 74 | 355 ± 75 | 0.37 |